NZ599161A - Method for activation of helper t cell and composition for use in the method - Google Patents

Method for activation of helper t cell and composition for use in the method

Info

Publication number: NZ599161A
Authority: NZ; New Zealand
Prior art keywords: peptide; dpb1; hla; acid sequence; expression vector
Prior art date: 2007-02-27

Application number

NZ599161A

Other languages

English (en)

Inventor

Haruo Sugiyama

Original Assignee

Int Inst Cancer Immunology Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-27

Filing date

2008-02-27

Publication date

2012-07-27

2008-02-27 Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc

2012-07-27 Publication of NZ599161A publication Critical patent/NZ599161A/xx

Links

230000004913 activation Effects 0.000 title 1
210000002443 helper t lymphocyte Anatomy 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 6
108010029618 HLA-DPB1*05:01 antigen Proteins 0.000 abstract 2
125000003275 alpha amino acid group Chemical group 0.000 abstract 2
239000013604 expression vector Substances 0.000 abstract 2
102000040430 polynucleotide Human genes 0.000 abstract 2
108091033319 polynucleotide Proteins 0.000 abstract 2
239000002157 polynucleotide Substances 0.000 abstract 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
DIIGDGJKTMLQQW-IHRRRGAJSA-N Arg-Lys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)N DIIGDGJKTMLQQW-IHRRRGAJSA-N 0.000 abstract 1
GGAPIOORBXHMNY-ULQDDVLXSA-N Lys-Arg-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)N)O GGAPIOORBXHMNY-ULQDDVLXSA-N 0.000 abstract 1
BKIFWLQFOOKUCA-DCAQKATOSA-N Met-His-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)O)N BKIFWLQFOOKUCA-DCAQKATOSA-N 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
DOXQMJCSSYZSNM-BZSNNMDCSA-N Phe-Lys-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O DOXQMJCSSYZSNM-BZSNNMDCSA-N 0.000 abstract 1
CICQXRWZNVXFCU-SRVKXCTJSA-N Ser-His-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O CICQXRWZNVXFCU-SRVKXCTJSA-N 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
238000012217 deletion Methods 0.000 abstract 1
230000037430 deletion Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000012986 modification Methods 0.000 abstract 1
230000004048 modification Effects 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
238000006467 substitution reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Hematology (AREA)
Oncology (AREA)
Wood Science & Technology (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Physics & Mathematics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)

NZ599161A 2007-02-27 2008-02-27 Method for activation of helper t cell and composition for use in the method NZ599161A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2007047317		2007-02-27
NZ578721A NZ578721A (en)	2007-02-27	2008-02-27	Method for activation of helper t cell and composition for use in the method

Publications (1)

Publication Number	Publication Date
NZ599161A true NZ599161A (en)	2012-07-27

Family

ID=39721287

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NZ578721A NZ578721A (en)	2007-02-27	2008-02-27	Method for activation of helper t cell and composition for use in the method
NZ599161A NZ599161A (en)	2007-02-27	2008-02-27	Method for activation of helper t cell and composition for use in the method
NZ599160A NZ599160A (en)	2007-02-27	2008-02-27	Method for activation of helper t cell and composition for use in the method

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NZ578721A NZ578721A (en)	2007-02-27	2008-02-27	Method for activation of helper t cell and composition for use in the method

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NZ599160A NZ599160A (en)	2007-02-27	2008-02-27	Method for activation of helper t cell and composition for use in the method

Country Status (26)

Country	Link
US (2)	US10139395B2 (es)
EP (1)	EP2119778B1 (es)
JP (2)	JP5225262B2 (es)
KR (1)	KR101598228B1 (es)
CN (6)	CN103149366B (es)
AU (1)	AU2008220031B2 (es)
BR (1)	BRPI0808084A2 (es)
CA (1)	CA2677075C (es)
CY (1)	CY1117150T1 (es)
DK (1)	DK2119778T3 (es)
ES (1)	ES2559062T3 (es)
HK (1)	HK1138321A1 (es)
HR (1)	HRP20160020T1 (es)
HU (1)	HUE027472T2 (es)
IL (1)	IL200161A (es)
MX (2)	MX352947B (es)
MY (2)	MY164867A (es)
NZ (3)	NZ578721A (es)
PL (1)	PL2119778T3 (es)
PT (1)	PT2119778E (es)
RU (2)	RU2009135802A (es)
SG (1)	SG177998A1 (es)
SI (1)	SI2119778T1 (es)
UA (1)	UA101608C2 (es)
WO (1)	WO2008105462A1 (es)
ZA (1)	ZA200905467B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2378264T3 (es)	2003-11-05	2012-04-10	International Institute Of Cancer Immunology, Inc.	Péptido antigénico de unión a HLA-DR derivado de WT1
CA2900087C (en)	2005-10-17	2024-02-13	Sloan Kettering Institute For Cancer Research	Wt1 hla class ii-binding peptides and compositions and methods comprising same
US9265816B2 (en)	2006-04-10	2016-02-23	Sloan Kettering Institute For Cancer Research	Immunogenic WT-1 peptides and methods of use thereof
NZ578721A (en)	2007-02-27	2012-04-27	Int Inst Cancer Immunology Inc	Method for activation of helper t cell and composition for use in the method
AR076349A1 (es)	2009-04-23	2011-06-01	Int Inst Cancer Immunology Inc	Peptido auxiliar del antigeno del cancer
SG181559A1 (en) *	2009-12-08	2012-07-30	Wolf Wilson Mfg Corp	Improved methods of cell culture for adoptive cell therapy
US8956860B2 (en)	2009-12-08	2015-02-17	Juan F. Vera	Methods of cell culture for adoptive cell therapy
TW201623616A (zh)	2010-10-05	2016-07-01	癌免疫研究所股份有限公司	用於活化細胞毒性ｔ細胞的方法及組成物，及用於細胞毒性ｔ細胞之活化誘導物
EP2757373A4 (en) *	2011-09-14	2015-07-01	Int Inst Cancer Immunology Inc	METHOD FOR MEASURING ANTI-WT1 ANTIBODIES
WO2013089252A1 (ja) *	2011-12-14	2013-06-20	国立大学法人高知大学	ヘルパーｔ細胞誘導性ポリペプチドの改変
WO2013106834A2 (en)	2012-01-13	2013-07-18	Memorial Sloan Kettering Cancer Center	Immunogenic wt-1 peptides and methods of use thereof
RU2680588C2 (ru) *	2012-09-12	2019-02-22	Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк.	Гены рецепторов антигенспецифичных хелперных т-клеток
CA2892660C (en) *	2012-12-17	2022-02-15	Otsuka Pharmaceutical Co., Ltd.	Method for activating helper t cell
LT2945647T (lt)	2013-01-15	2021-02-25	Memorial Sloan Kettering Cancer Center	Imunogeniniai wt-1 peptidai ir jų panaudojimo būdai
US10815273B2 (en)	2013-01-15	2020-10-27	Memorial Sloan Kettering Cancer Center	Immunogenic WT-1 peptides and methods of use thereof
JP6005305B2 (ja) *	2014-02-26	2016-10-12	テラ株式会社	Ｗｔ１抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤
WO2016208332A1 (ja)	2015-06-25	2016-12-29	国立大学法人神戸大学	経口腫瘍ワクチン
US11666646B2 (en)	2016-12-26	2023-06-06	National University Corporation Kobe University	Cancer therapy utilizing combination of oral tumor vaccine and immunosuppression inhibitor
CN116196405A (zh)	2019-12-31	2023-06-02	伊利克斯根治疗公司	核酸和蛋白质向细胞和组织的基于温度的瞬时递送
KR102647825B1 (ko) *	2021-07-22	2024-03-14	서울대학교산학협력단	항-hla-dp 단클론 항체 및 이의 용도

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5726288A (en)	1989-11-13	1998-03-10	Massachusetts Institute Of Technology	Localization and characterization of the Wilms' tumor gene
DE69940264D1 (de)	1998-07-31	2009-02-26	Int Inst Cancer Immunology Inc	Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
US7063854B1 (en)	1998-09-30	2006-06-20	Corixa Corporation	Composition and methods for WTI specific immunotherapy
EP1117687B1 (en)	1998-09-30	2008-06-25	Corixa Corporation	Compositions and methods for wt1 specific immunotherapy
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
EP1261711A2 (en)	2000-02-22	2002-12-04	Corixa Corporation	Compositions and methods for diagnosis and therapy of malignant mesothelioma
ATE383375T1 (de) *	2001-03-22	2008-01-15	Int Inst Cancer Immunology Inc	Wti-modifiziertes peptid
GB0108491D0 (en)	2001-04-04	2001-05-23	Gendaq Ltd	Engineering zinc fingers
JP4229832B2 (ja)	2001-06-29	2009-02-25	忠範真弓	癌抑制遺伝子ｗｔ１の産物に基づく癌抗原とカチオン性リポソームとを含んで成る癌ワクチン
US7553494B2 (en) *	2001-08-24	2009-06-30	Corixa Corporation	WT1 fusion proteins
EP1447091A4 (en)	2001-09-28	2008-02-13	Institute Of Can International	NEW METHOD FOR INDUCTION OF ANTIGEN SPECIFIC T CELLS
EP1447092A4 (en)	2001-09-28	2007-07-11	Haruo Sugiyama	METHODS OF INDUCING ANTIGEN-SPECIFIC T CELLS
CN100408683C (zh)	2002-06-12	2008-08-06	株式会社国际癌症免疫研究所	Hla-a24限制性癌抗原肽
AU2003262094A1 (en)	2002-09-12	2004-04-30	Haruo Sugiyama	Cancer antigen peptide preparation
JP4480580B2 (ja)	2002-09-20	2010-06-16	株式会社癌免疫研究所	Ｗｔ１置換型ペプチド
ES2332590T3 (es)	2003-01-15	2010-02-09	International Institute Of Cancer Immunology, Inc.	Dimero peptidico.
EP1640458B1 (en)	2003-06-27	2011-12-28	International Institute of Cancer Immunology, Inc.	Method of selecting patients suitable for wt1 vaccine
ES2378264T3 (es) *	2003-11-05	2012-04-10	International Institute Of Cancer Immunology, Inc.	Péptido antigénico de unión a HLA-DR derivado de WT1
WO2005053618A2 (en) *	2003-12-01	2005-06-16	Sloan-Kettering Institute For Cancer Research	Synthetic hla binding peptide analogues and uses thereof
DK2186896T3 (en)	2004-03-31	2015-12-21	Int Inst Cancer Immunology Inc	Cancer antigen peptides derived from WT1
JP4719876B2 (ja)	2005-04-04	2011-07-06	国立大学法人愛媛大学	Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
CA2900087C (en)	2005-10-17	2024-02-13	Sloan Kettering Institute For Cancer Research	Wt1 hla class ii-binding peptides and compositions and methods comprising same
ES2352855T3 (es)	2005-11-30	2011-02-23	International Institute Of Cancer Immunology, Inc.	Nuevos compuestos peptídicos del tumor de wilms.
AU2007218649B2 (en)	2006-02-22	2013-01-10	International Institute Of Cancer Immunology, Inc.	HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same
US9265816B2 (en)	2006-04-10	2016-02-23	Sloan Kettering Institute For Cancer Research	Immunogenic WT-1 peptides and methods of use thereof
ES2556831T3 (es)	2006-12-28	2016-01-20	International Institute Of Cancer Immunology, Inc.	Péptido de WT1 restringido a HLA-A*1101 y composiciones farmacéuticas que contienen al mismo
NZ578721A (en)	2007-02-27	2012-04-27	Int Inst Cancer Immunology Inc	Method for activation of helper t cell and composition for use in the method
WO2008108257A1 (ja)	2007-03-05	2008-09-12	International Institute Of Cancer Immunology, Inc.	癌抗原特異的ｔ細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用
AR076349A1 (es) *	2009-04-23	2011-06-01	Int Inst Cancer Immunology Inc	Peptido auxiliar del antigeno del cancer
TW201623616A (zh)	2010-10-05	2016-07-01	癌免疫研究所股份有限公司	用於活化細胞毒性ｔ細胞的方法及組成物，及用於細胞毒性ｔ細胞之活化誘導物
CA2892660C (en)	2012-12-17	2022-02-15	Otsuka Pharmaceutical Co., Ltd.	Method for activating helper t cell

2008
- 2008-02-27 NZ NZ578721A patent/NZ578721A/en unknown
- 2008-02-27 CN CN201310058504.4A patent/CN103149366B/zh active Active
- 2008-02-27 KR KR1020097017594A patent/KR101598228B1/ko active IP Right Grant
- 2008-02-27 BR BRPI0808084-4A patent/BRPI0808084A2/pt not_active Application Discontinuation
- 2008-02-27 CN CN201410573477.9A patent/CN104312974B/zh active Active
- 2008-02-27 RU RU2009135802/10A patent/RU2009135802A/ru unknown
- 2008-02-27 HU HUE08712039A patent/HUE027472T2/en unknown
- 2008-02-27 SI SI200831564T patent/SI2119778T1/sl unknown
- 2008-02-27 MX MX2014002596A patent/MX352947B/es unknown
- 2008-02-27 UA UAA200909812A patent/UA101608C2/uk unknown
- 2008-02-27 MY MYPI2013001057A patent/MY164867A/en unknown
- 2008-02-27 DK DK08712039.0T patent/DK2119778T3/en active
- 2008-02-27 RU RU2014104572A patent/RU2680539C2/ru active
- 2008-02-27 CN CN201310009095.9A patent/CN103103246B/zh active Active
- 2008-02-27 NZ NZ599161A patent/NZ599161A/xx unknown
- 2008-02-27 EP EP08712039.0A patent/EP2119778B1/en active Active
- 2008-02-27 CN CN201310009518.7A patent/CN103088103B/zh active Active
- 2008-02-27 MY MYPI20093253A patent/MY158219A/en unknown
- 2008-02-27 US US12/449,765 patent/US10139395B2/en active Active
- 2008-02-27 MX MX2009009168A patent/MX2009009168A/es active IP Right Grant
- 2008-02-27 CN CN200880006096A patent/CN101622344A/zh active Pending
- 2008-02-27 NZ NZ599160A patent/NZ599160A/en unknown
- 2008-02-27 WO PCT/JP2008/053417 patent/WO2008105462A1/ja active Application Filing
- 2008-02-27 SG SG2012004180A patent/SG177998A1/en unknown
- 2008-02-27 ES ES08712039.0T patent/ES2559062T3/es active Active
- 2008-02-27 PL PL08712039T patent/PL2119778T3/pl unknown
- 2008-02-27 AU AU2008220031A patent/AU2008220031B2/en active Active
- 2008-02-27 PT PT87120390T patent/PT2119778E/pt unknown
- 2008-02-27 JP JP2009501276A patent/JP5225262B2/ja active Active
- 2008-02-27 CA CA2677075A patent/CA2677075C/en active Active
- 2008-02-27 CN CN201510102294.3A patent/CN104774910B/zh active Active
2009
- 2009-07-30 IL IL200161A patent/IL200161A/en active IP Right Grant
- 2009-08-05 ZA ZA200905467A patent/ZA200905467B/xx unknown
2010
- 2010-05-04 HK HK10104389.9A patent/HK1138321A1/xx unknown
2013
- 2013-01-31 JP JP2013017370A patent/JP5714619B2/ja active Active
2016
- 2016-01-11 HR HRP20160020TT patent/HRP20160020T1/hr unknown
- 2016-01-20 CY CY20161100054T patent/CY1117150T1/el unknown
2018
- 2018-10-18 US US16/163,682 patent/US11555814B2/en active Active

Also Published As

Publication number	Publication date
MX352947B (es)	2017-12-14
RU2680539C2 (ru)	2019-02-22
KR20090125067A (ko)	2009-12-03
ES2559062T3 (es)	2016-02-10
ZA200905467B (en)	2010-05-26
KR101598228B1 (ko)	2016-02-26
CN103088103B (zh)	2015-09-30
NZ599160A (en)	2012-07-27
PL2119778T3 (pl)	2016-04-29
CN104774910B (zh)	2018-04-10
SI2119778T1 (sl)	2016-03-31
UA101608C2 (uk)	2013-04-25
CN104312974B (zh)	2018-09-04
JPWO2008105462A1 (ja)	2010-06-03
CN103103246A (zh)	2013-05-15
JP5225262B2 (ja)	2013-07-03
NZ578721A (en)	2012-04-27
IL200161A (en)	2015-11-30
CN103088103A (zh)	2013-05-08
JP5714619B2 (ja)	2015-05-07
MX2009009168A (es)	2009-09-07
EP2119778B1 (en)	2015-11-04
AU2008220031B2 (en)	2013-06-13
CN104774910A (zh)	2015-07-15
CN104312974A (zh)	2015-01-28
PT2119778E (pt)	2016-02-15
RU2009135802A (ru)	2011-04-10
CA2677075C (en)	2018-07-10
US11555814B2 (en)	2023-01-17
RU2014104572A (ru)	2015-08-20
AU2008220031A1 (en)	2008-09-04
HRP20160020T1 (hr)	2016-02-12
CN103103246B (zh)	2018-05-01
HUE027472T2 (en)	2016-09-28
IL200161A0 (en)	2011-08-01
DK2119778T3 (en)	2016-01-25
CN103149366A (zh)	2013-06-12
CN101622344A (zh)	2010-01-06
SG177998A1 (en)	2012-02-28
MY158219A (en)	2016-09-15
EP2119778A1 (en)	2009-11-18
US20200064332A1 (en)	2020-02-27
CA2677075A1 (en)	2008-09-04
EP2119778A4 (en)	2010-08-18
CY1117150T1 (el)	2017-04-05
HK1138321A1 (en)	2010-08-20
MY164867A (en)	2018-01-30
CN103149366B (zh)	2018-06-15
US20100247556A1 (en)	2010-09-30
BRPI0808084A2 (pt)	2014-07-22
WO2008105462A1 (ja)	2008-09-04
JP2013139448A (ja)	2013-07-18
US10139395B2 (en)	2018-11-27

Legal Events

Date	Code	Title	Description
2012-11-30	PSEA	Patent sealed
2013-03-28	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 FEB 2015 BY HENRY HUGHES Effective date: 20130311
2014-09-26	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 FEB 2018 BY HENRY HUGHES IP LIMITED Effective date: 20140909
2018-01-26	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 FEB 2019 BY HENRY HUGHES IP LIMITED Effective date: 20180108
2019-01-25	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 FEB 2020 BY HENRY HUGHES IP LIMITED Effective date: 20190124
2020-01-31	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 FEB 2021 BY HENRY HUGHES IP LIMITED Effective date: 20200127
2021-01-29	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 FEB 2022 BY HENRY HUGHES IP LIMITED Effective date: 20210126
2022-01-28	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 FEB 2023 BY HENRY HUGHES IP LIMITED Effective date: 20220118
2023-01-27	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 FEB 2024 BY HENRY HUGHES IP LIMITED Effective date: 20230125
2024-01-26	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 FEB 2025 BY HENRY HUGHES IP LIMITED Effective date: 20240124

Publication	Publication Date	Title
NZ599161A (en)	2012-07-27	Method for activation of helper t cell and composition for use in the method
MX2008009493A (es)	2008-10-03	Peptido novedoso y uso del mismo.
NZ621196A (en)	2015-08-28	Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
TWI455721B (zh)	2014-10-11	癌疫苗組合物
NZ603028A (en)	2014-11-28	Tfpi inhibitors and methods of use
RU2011132212A (ru)	2013-02-10	Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция
NZ602471A (en)	2014-10-31	Antagonists of activin-actriia and uses for increasing red blood cell levels
PE20121393A1 (es)	2012-10-26	Analogo peptidico de oxintomodulina
WO2009025196A1 (ja)	2009-02-26	Foxm1ペプチドおよびこれを含む薬剤
NZ602845A (en)	2015-05-29	Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
NZ707292A (en)	2017-06-30	Activin-actrii antagonists and uses for increasing red blood cell levels
MX2012008999A (es)	2012-08-31	Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es)	2012-08-31	Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es)	2012-08-31	Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX348464B (es)	2017-06-14	Agente inductor de inmunidad.
NZ603348A (en)	2014-05-30	Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
UA111141C2 (uk)	2016-04-11	Рекомбінантні антигени рсв
NZ600732A (en)	2014-06-27	Oxyntomodulin peptide analogue
WO2011038900A3 (en)	2011-06-23	Peptide analogues of glucagon for diabetes therapy
MX2010002018A (es)	2010-05-27	Peptido de cdh3 y agente medicinal que comprende al mismo.
NZ596043A (en)	2013-05-31	Allergy inhibitor compositions and kits and methods of using the same
WO2009038026A1 (ja)	2009-03-26	Ｃｔｌ誘導剤組成物
NZ609916A (en)	2015-03-27	Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
MX337756B (es)	2016-03-17	Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo.
NZ614557A (en)	2015-03-27	Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use